Drug resistance is a significant challenge of daily oncology practice. Docetaxel and gossypol both have antitumoral activity in hormone-refractory prostate cancer (HRPC). Our results revealed that docetaxel and gossypol were synergistically cytotoxic and apoptotic in PC-3 cells in a dose- and time-dependent manner. We further investigated the expression profiles of genes involved in drug resistance and metabolism with a Human Cancer Drug Resistance and Metabolism PCR Array(A (R)) (SuperArray). Six of the 84 genes that are known to regulate drug resistance, metabolism, cell cycle, DNA repair and oncogenesis were downregulated a parts per thousand yen3-fold change by the combination treatment. These results may be important in devising mechan...
Abstract Background Overcoming drug resistance is cri...
International audienceDocetaxel is used as a standard treatment in patients with metastatic castrati...
Castration-resistant prostate cancer (CRPC) is now the second most common cause of male cancer-relat...
PubMed ID: 19288219Drug resistance is a significant challenge of daily oncology practice. Docetaxel ...
WOS: 000296212300016Objective: Docetaxel has become the standard of care for hormone-refractory pros...
Docetaxel is the first-line standard treatment for castration-resistant prostate cancer. However, re...
Docetaxel is the first-line standard treatment for castration-resistant prostate cancer. However, re...
Objective: Docetaxel has become the standard of care for hormone-refractory prostate cancer (HRPC), ...
Docetaxel is the first-line standard treatment for castration-resistant prostate cancer. However, re...
Docetaxel is the first-line standard treatment for castration-resistant prostate cancer. However, re...
Docetaxel is the first-line standard treatment for castration resistant prostate cancer (CRPC). Howe...
Molecular characterization of radical prostatectomy specimens after systemic therapy may identify a ...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...
Molecular characterization of radical prostatectomy specimens after systemic therapy may identify a ...
Based on a molecular classification of prostate cancer using gene expression pathway signatures, we ...
Abstract Background Overcoming drug resistance is cri...
International audienceDocetaxel is used as a standard treatment in patients with metastatic castrati...
Castration-resistant prostate cancer (CRPC) is now the second most common cause of male cancer-relat...
PubMed ID: 19288219Drug resistance is a significant challenge of daily oncology practice. Docetaxel ...
WOS: 000296212300016Objective: Docetaxel has become the standard of care for hormone-refractory pros...
Docetaxel is the first-line standard treatment for castration-resistant prostate cancer. However, re...
Docetaxel is the first-line standard treatment for castration-resistant prostate cancer. However, re...
Objective: Docetaxel has become the standard of care for hormone-refractory prostate cancer (HRPC), ...
Docetaxel is the first-line standard treatment for castration-resistant prostate cancer. However, re...
Docetaxel is the first-line standard treatment for castration-resistant prostate cancer. However, re...
Docetaxel is the first-line standard treatment for castration resistant prostate cancer (CRPC). Howe...
Molecular characterization of radical prostatectomy specimens after systemic therapy may identify a ...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...
Molecular characterization of radical prostatectomy specimens after systemic therapy may identify a ...
Based on a molecular classification of prostate cancer using gene expression pathway signatures, we ...
Abstract Background Overcoming drug resistance is cri...
International audienceDocetaxel is used as a standard treatment in patients with metastatic castrati...
Castration-resistant prostate cancer (CRPC) is now the second most common cause of male cancer-relat...